BioInsights - Regulatory requirements and product attributes for cGMP viral vector production

Regulatory requirements and product attributes for cGMP viral vector production

Cell & Gene Therapy Insights 2022; 8(11), 1353

DOI: 10.18609/cgti.2022.196

Published: 19 December 2022
Poster
Scott Cross, Shikha Mishra

Navigating the constantly evolving regulatory landscape in cell and gene therapy manufacturing can pose critical challenges for developers and manufacturers. Failure to meet requirements can significantly raise costs, motivating the implementation of robust, reproducible, and compliant processes.